Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion description "[Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion evidence source_evidence_literature NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion SIO_000772 23561477 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion wasDerivedFrom befree-20140225 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion wasGeneratedBy ECO_0000203 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- befree-20140225 importedOn "2014-02-25" NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.